Adrienne Clements-Egan, Ph.D. joined Larimar Therapeutics in June 2023 as Vice President, Bioanalytics and Developability after over 16 years of experience in biotherapeutics development. Dr. Clements-Egan began her biotherapeutics career at Centocor, R&D, a wholly owned subsidiary of Johnson and Johnson, where she developed and oversaw a protein biochemistry team within the bioanalytical department. She later progressed through positions of increasing scope and responsibility at Centocor (and later, Janssen) in the fields of immunogenicity and bioanalysis. She most recently served as a Senior Scientific Director of Bioanalysis, Target Engagement, and Receptor Occupancy assessments for Janssen. In this capacity, Dr. Clements-Egan oversaw a group of 40+ Janssen employees and additional flexstaff who executed internal and outsourced projects to provide bioanalytical solutions for Janssen’s biotherapeutic pipeline. Dr. Clements-Egan provided bioanalytical and Immunogenicity expertise to numerous novel biotherapeutic programs, including 5 approved therapeutic antibodies, 2 approved bispecifics, and one approved CAR-T cell therapy.
Dr. Clements-Egan has been an active member of the American Association of Pharmaceutical Sciences, where she served as a Steering Committee Member of The Therapeutic Protein Immunogenicity Focus Group, the chair of an eLearning committee for AAPS educational webinars, and the designer of a multi-lecture curriculum for the first AAPS e-course on Immunogenicity. Dr. Clements-Egan obtained her Ph.D. in Biochemistry and Molecular Biophysics at the University of Pennsylvania, where she studied protein structure-function relationships.